Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50
Conditions: COVID-19; SARS-CoV-2 Interventions: Drug: Ivermectin; Drug: Placebo Sponsor: Insud Pharma Terminated (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 15, 2023 Category: Research Source Type: clinical trials
The Safety and Tolerability of MY-586 COVID-19 Neutralizing Antibody Nasal Spray in Healthy Subjects
Conditions: SARS-CoV-2; Prevention Interventions: Biological: MY-586 SARS-CoV-2 Neutralizing Antibody nasal spray; Other: Placebo Comparator: MY-586 SARS-CoV-2 Neutralization Antibody nasal excipient Sponsor: The Second Affiliated Hospital of Chongqing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 4, 2023 Category: Research Source Type: clinical trials
A Phase 2/3 Open-Label Study to Evaluate the Safety and Immunogenicity of an XBB.1.5 (Omicron Subvariant) SARS CoV-2 rS Vaccine.
Condition: COVID-19 Interventions: Biological: XBB.1.5 Vaccine (Booster); Biological: XBB.1.5 Vaccine (single dose) Sponsor: Novavax Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 3, 2023 Category: Research Source Type: clinical trials
